Hage R, Elbers J R, Brutel de la Rivière A, van den Bosch J M
Department of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands.
Thorax. 1998 Jun;53(6):450-3. doi: 10.1136/thx.53.6.450.
Combined type small cell lung cancer (SCLC) has been reported to occur in, at most, 1% of all cases of SCLC. These tumours consist of SCLC with a component of squamous cell carcinoma and/or adenocarcinoma. The survival of patients with combined and pure SCLC after surgical resection was assessed.
From 1977 to 1994 2115 patients with bronchogenic carcinoma underwent pulmonary resection. From this group 26 patients (1.2%) were diagnosed as having combined SCLC and 74 patients (3.5%) as having pure SCLC.
From the 26 patients with combined SCLC (mean age 66.4 years) three were classified as pT1N0M0, eight as pT2N0M0, four as postoperative stage II, and 11 as postoperative stage III. Histological examination showed a component of squamous cell carcinoma in 21 patients. There were 18 (69%) lobectomies, seven (27%) pneumonectomies, and one (4%) segmentectomy. In all patients surgery was thought to be curative. Overall hospital mortality was 4% (n = 1). Cumulative five year survival was 31% for all hospital survivors with combined SCLC postoperative stage I, 50% for those with pT1N0M0, and 25% for those with pT2N0M0 disease. No patients with postoperative stage II and III disease survived for five years. In the 74 patients with pure SCLC hospital mortality was 3% (n = 2); cumulative five year survival was 39% in patients with postoperative stage I disease, 46% for those with pT1N0M0 and 35% for those with pT2N0M0. When compared with pure SCLC, no significant differences in five year survival were evident in patients with postoperative stage I disease.
Surgical resection in patients with combined SCLC postoperative stage I yields a cumulative five year survival of 31% while for those with stage II and III disease there were no survivors at five years. In patients with stage I combined or pure SCLC surgery can offer a long term disease free interval or may even be curative.
据报道,混合型小细胞肺癌(SCLC)在所有SCLC病例中最多占1%。这些肿瘤由SCLC与鳞状细胞癌和/或腺癌成分组成。评估了手术切除后混合型和单纯型SCLC患者的生存率。
1977年至1994年,2115例支气管源性癌患者接受了肺切除术。在该组中,26例(1.2%)被诊断为混合型SCLC,74例(3.5%)为单纯型SCLC。
26例混合型SCLC患者(平均年龄66.4岁)中,3例被分类为pT1N0M0,8例为pT2N0M0,4例为术后Ⅱ期,11例为术后Ⅲ期。组织学检查显示21例患者有鳞状细胞癌成分。有18例(69%)肺叶切除术,7例(27%)全肺切除术,1例(4%)肺段切除术。所有患者的手术均被认为是根治性的。总体医院死亡率为4%(n = 1)。所有术后Ⅰ期混合型SCLC医院幸存者的累积五年生存率为31%,pT1N0M0患者为50%,pT2N0M0疾病患者为25%。没有术后Ⅱ期和Ⅲ期疾病的患者存活五年。在74例单纯型SCLC患者中,医院死亡率为3%(n = 2);术后Ⅰ期疾病患者的累积五年生存率为39%,pT1N0M0患者为46%,pT2N0M0患者为35%。与单纯型SCLC相比,术后Ⅰ期疾病患者的五年生存率无明显差异。
术后Ⅰ期混合型SCLC患者手术切除后的累积五年生存率为31%,而Ⅱ期和Ⅲ期疾病患者五年无幸存者。对于Ⅰ期混合型或单纯型SCLC患者,手术可提供长期无病生存期,甚至可能治愈。